European guidelines on managing adverse effects of medication for ADHD - PubMed (original) (raw)

Practice Guideline

doi: 10.1007/s00787-010-0140-6. Epub 2010 Nov 3.

T Banaschewski, J Buitelaar, D Coghill, M Danckaerts, R W Dittmann, M Döpfner, R Hamilton, C Hollis, M Holtmann, M Hulpke-Wette, M Lecendreux, E Rosenthal, A Rothenberger, P Santosh, J Sergeant, E Simonoff, E Sonuga-Barke, I C K Wong, A Zuddas, H-C Steinhausen, E Taylor; European Guidelines Group

Affiliations

• PMID: 21042924
• PMCID: PMC3012210
• DOI: 10.1007/s00787-010-0140-6

Practice Guideline

European guidelines on managing adverse effects of medication for ADHD

J Graham et al. Eur Child Adolesc Psychiatry. 2011 Jan.

Abstract

The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.

PubMed Disclaimer

Figures

Fig. 1

Recommendation for blood pressure (BP) monitoring and management in ADHD patients

Similar articles

• ADHD update: new data on the risks of medication.
  [No authors listed] [No authors listed] Harv Ment Health Lett. 2006 Oct;23(4):3-5. Harv Ment Health Lett. 2006. PMID: 17183739 No abstract available.
• Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
  Garnock-Jones KP, Keating GM. Garnock-Jones KP, et al. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. Paediatr Drugs. 2009. PMID: 19445548 Review.
• Pharmacologic treatment of ADHD: road conditions in driving patients to successful outcomes.
  Manos MJ. Manos MJ. Medscape J Med. 2008 Jan 8;10(1):5. Medscape J Med. 2008. PMID: 18324315 Free PMC article. Review.
• Sleep disturbances and ADHD medications.
  Rostain AL. Rostain AL. Curr Psychiatry Rep. 2007 Oct;9(5):399-400. doi: 10.1007/s11920-007-0051-5. Curr Psychiatry Rep. 2007. PMID: 17915079 No abstract available.
• Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
  Eiland LS, Bell EA, Erramouspe J. Eiland LS, et al. Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30. Ann Pharmacother. 2014. PMID: 24982313 Review.

Cited by

• An inventory of European data sources for the long-term safety evaluation of methylphenidate.
  Murray ML, Insuk S, Banaschewski T, Neubert AC, McCarthy S, Buitelaar JK, Coghill D, Dittmann RW, Konrad K, Panei P, Rosenthal E, Sonuga-Barke EJ, Wong IC. Murray ML, et al. Eur Child Adolesc Psychiatry. 2013 Oct;22(10):605-18. doi: 10.1007/s00787-013-0386-x. Epub 2013 Mar 19. Eur Child Adolesc Psychiatry. 2013. PMID: 23508655 Free PMC article.
• Updates on treatment of attention-deficit/hyperactivity disorder: facts, comments, and ethical considerations.
  Rothenberger A, Rothenberger LG. Rothenberger A, et al. Curr Treat Options Neurol. 2012 Dec;14(6):594-607. doi: 10.1007/s11940-012-0197-2. Curr Treat Options Neurol. 2012. PMID: 22968494 Free PMC article.
• Does Methylphenidate Work in Children and Adolescents with Attention Deficit Hyperactivity Disorder?
  Pereira Ribeiro J, Arthur EJ, Gluud C, Simonsen E, Storebø OJ. Pereira Ribeiro J, et al. Pediatr Rep. 2021 Aug 1;13(3):434-443. doi: 10.3390/pediatric13030050. Pediatr Rep. 2021. PMID: 34449694 Free PMC article.
• Association Between Medication Use and Performance on Higher Education Entrance Tests in Individuals With Attention-Deficit/Hyperactivity Disorder.
  Lu Y, Sjölander A, Cederlöf M, D'Onofrio BM, Almqvist C, Larsson H, Lichtenstein P. Lu Y, et al. JAMA Psychiatry. 2017 Aug 1;74(8):815-822. doi: 10.1001/jamapsychiatry.2017.1472. JAMA Psychiatry. 2017. PMID: 28658471 Free PMC article.
• Pediatric psychopharmacology: Too much and too little.
  Taylor E. Taylor E. World Psychiatry. 2013 Jun;12(2):124-5. doi: 10.1002/wps.20030. World Psychiatry. 2013. PMID: 23737414 Free PMC article. No abstract available.

References

1. 1. (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56:1073–1086 - PubMed
2. 1. (2001) Methylphenidate and narcolepsy: new indication. When modafinil fails. Prescrire Int 10:7–9 - PubMed
3. 1. (2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58:527–536 - PubMed
4. 1. (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576 - PubMed
5. 1. Aagaard L, Weber CB, Hansen EH. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007. Drug Saf. 2010;33:327–339. doi: 10.2165/11319100-000000000-00000. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Springer

• Medical

  • MedlinePlus Health Information